north american investment partners, page-4

Seems to me that there are some yet to be determined parameters that will ultimately decide the $$$’s needed to fund Cvac phase 3.
These would include:
- the number of participants, (I’ve seen guesstimates for Cvac trial as low as 65, Dendreon had 512)
- the parameters to be tested. eg a survival rate trial will take longer than one testing for a positive response to the treatment. Shorter trial, lower cost
- the number of trial sites, etc.

I guess most of us have pondered on what the Phase 3 trial cost will be and whether the available funds are already enough. What are the available funds?
Dec 2008 SPP $200,000
Mar 2009 placement $1,500,000
Fortrend placement up to $12,000,000
Current SPP up to $3,000,000

That’s about $17 million by my reckoning. Enough? I don’t know.

I guess that once the IND process with FDA leads to agreement on the final trial parameters, PRR management will have a better idea of what’s needed. Or perhaps they already know and are after $$$'s?

Logical to hold one EGM to gain approval for the lot though.

If the SPP is to be successful then current SP is very attractive

Looking forward to announcements. Good luck all.